Neurocrine Biosciences, Inc. (NBIX)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Neurocrine Biosciences, Inc. keeps $18 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 10
in 83 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a biotechnology company listed on the NASDAQ Global Select Market under NBIX that develops and commercializes treatments for neurological, neuropsychiatric, and endocrine-related disorders. In FY2025, revenue was $2.9 billion, spanning commercial medicines and clinical-stage drug candidates.
Today's Snapshot
NBIX closed 1.8% lower at 162.86, in line with a weaker sector.
Trading Volume
Above 10d avg 1.4M
1.5M
vs S&P 500 Today
Underperforming Market
-1.58%
Updated: November 18, 2026 at 21:30 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$148.64 - $164.40Buy
- RSI (14)57.31Neutral
- Stochastic %K (14, 3, 3)68.16Neutral
- MACD Level (12, 26)5.88Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.